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Abstract
Background: Genome editing of malaria parasites is key to the generation of live attenuated parasites used in
experimental vaccination approaches. DNA repair in Plasmodium generally occurs only through homologous
recombination. This has been used to generate transgenic parasites that lack one to three genes, leading to
developmental arrest in the liver and allowing the host to launch a protective immune response. While effective in
principle, this approach is not safe for use in humans as single surviving parasites can still cause disease. Here we
use zinc-finger nucleases to generate attenuated parasite lines lacking an entire chromosome arm, by a timed
induction of a double-strand break. Rare surviving parasites also allow the investigation of unconventional DNA
repair mechanisms in a rodent malaria parasite.
Results: A single, zinc-finger nuclease-induced DNA double-strand break results in the generation of attenuated
parasite lines that show varying degrees of developmental arrest, protection efficacy in an immunisation regime
and safety, depending on the timing of zinc-finger nuclease expression within the life cycle. We also identify DNA
repair by microhomology-mediated end joining with as little as four base pairs, resulting in surviving parasites and
thus breakthrough infections.
Conclusions: Malaria parasites can repair DNA double-strand breaks with surprisingly small mini-homology
domains located across the break point. Timely expression of zinc-finger nucleases could be used to generate a
new generation of attenuated parasite lines lacking hundreds of genes.
Keywords: Apicomplexa, Plasmodium, Malaria, Genetically attenuated parasites, Vaccine, Zinc-finger nucleases,
Alternative end joining, Microhomology-mediated end joining, Alternative DNA repair, DSB
Background
Malaria poses a heavy health and economical burden in
endemic countries and is caused by apicomplexan para-
sites of the genus Plasmodium. More than one billion
people are at risk of infection and fatalities occur mainly
in children aged under 5 years [1]. Plasmodium infection
results in a weak and mostly short-lived semi-immunity
resulting in frequent re-infection with slowly decreasing
severity under continuous exposure [2, 3]. In the field,
Plasmodium falciparum parasites have readily acquired
resistance to most antimalarial drugs by both point mu-
tations and gene copy number variations [4, 5]. In vitro
drug resistance selection was shown to be initiated by
duplications of large genomic regions flanked by natur-
ally occurring A/T repeats. After the initial duplication,
this locus was further expanded by more efficient
homology-based mechanisms [6]. This massive expan-
sion confers some drug resistance but also has a high
metabolic cost for the parasite, as multiple unrelated
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genes are co-amplified. It is believed that the process of
copy number variation, followed by point mutations
conferring resistance and a subsequent homology-based
de-amplification, leads to the fast appearance of drug-
resistant parasites in the field [7].
Malaria parasites are transmitted during a bite of in-
fected female Anopheles mosquitoes. Injected into the
skin these Plasmodium sporozoites rapidly migrate and
enter blood vessels [8]. They disperse within the blood
through the mammalian body and specifically arrest in
the liver, where they invade hepatocytes, replicate and
differentiate into red blood cell-invading forms that ul-
timately cause the disease [9]. No infection-blocking vac-
cine is currently available for malaria, as is the case for
all other human diseases caused by eukaryotic pathogens
[10]. The gold standard of experimental immunisation
against Plasmodium and other parasites like Schistosoma
is repeated infection with radiation-attenuated parasites
[11, 12]. In the case of Plasmodium, γ-irradiation of spo-
rozoites is assumed to cause random double-strand
breaks (DSBs) in the genome as well as RNA damage,
resulting in surviving parasites which still actively invade
liver cells but soon arrest in development and elicit a
protective immune response [13].
Attempts have been made to replicate this phenotype
in a consistent and genetically defined manner by gener-
ating deletion mutants of genes essential for liver stage
development [14–16]. These genetically attenuated para-
sites (GAPs) are generally more consistent in their tim-
ing of arrest than radiation attenuated sporozoites and
are a reproducible, standardised source for attenuated
parasites. GAPs have been classified into early and late
liver stage-arresting parasites [17–19]. Multiple genes
have been exploited for the generation of GAPs in ro-
dent malaria parasites [20]. Triple immunisation with
live GAP sporozoites can elicit sterile protection against
a subsequent challenge with wild-type (WT) parasites
[14]. However, many GAPs show breakthrough infec-
tions during immunisation, resulting in a full-blown
pathological blood-stage infection, and these have not al-
ways been consistent in the two main model parasites,
Plasmodium berghei and Plasmodium yoelii [16]. Transfer
of data obtained in rodent-infecting Plasmodium models
to the major human malaria parasite P. falciparum has,
therefore, been challenging. It is currently assumed that
multiple (up to triple) gene deletions in a single parasite
are needed to reduce breakthrough infections to zero.
However, a final verdict is still open due to the limitation
of the testable range for parasites and mice/human volun-
teers under pre-clinical conditions [21, 22].
The genome of Plasmodium is haploid, with the ex-
ception of the zygote (2n1c) and the resulting ookinete
(2n2c), which is the form that invades the mosquito
midgut (Fig. 1a) and transforms into the diploid oocyst.
Replicating stages of Plasmodium, the oocyst during
sporogony as well as the liver- and intra-erythrocytic
stages contain nuclei with multiple (sometimes thou-
sands) genome copies in a single cell. Genetic modifica-
tion in Plasmodium utilises transfection of plasmid
DNA and its exclusive integration via homologous re-
combination (HR) in blood stage parasites [23, 24]. In
contrast, the related apicomplexan parasite Toxoplasma
gondii mainly employs non-homologous end joining
(NHEJ) as the primary DNA repair pathway. In this
species genes involved in the NHEJ pathway, includ-
ing Ku70/80, were readily identified. A T. gondii para-
site line lacking Ku80 can only perform HR, thus
allowing efficient targeted gene modification via HR
[25]. Genes involved in NHEJ have so far not been
identified in any Plasmodium species [26, 27]. Also,
recent data suggest that alternative DNA repair can
occur in P. falciparum [27].
The generation of live attenuated sporozoites suffers
from the lack of a clear list of target genes that, when
deleted, can be predicted to cause the desired effect, i.e.
developmental arrest in the liver without breakthrough
infections. We propose that a well-timed and tightly regu-
lated expression of zinc-finger nucleases (ZFNs) will result
in a DSB that the parasites — in the absence of the NHEJ
machinery or a plasmid repair template for HR — cannot
repair [28]. This should result in parasite death after the
next nuclear division, as they would lose the part of the
cut chromosome lacking the centromere and thus tens to
hundreds of genes. Properly engineered and timed, such
parasites could be used as next-generation attenuated ex-
perimental vaccines. In addition, the set of parasites
needed to evaluate attenuation capacity should allow us to
probe alternative DNA repair mechanisms.
Results
Generation of P. berghei parasites expressing ZFNs in
mosquito and liver stages
Many genes in Plasmodium are expressed only during a
certain developmental stage of the parasite [29], provid-
ing proteins needed for specific functions such as adhe-
sion to a host cell. In order to induce ZFN-mediated
DSBs during mosquito-to-mouse transmission, we se-
lected four well-characterised, stage-specific promoters
to control ZFN expression. These promoters provide de-
fined and tightly regulated transcription profiles in the
mosquito and during the liver stage but are otherwise si-
lent. The promoter of the gene encoding the circum-
sporozoite protein (CSP) is active from the mid-oocyst
stage to the liver stage [30] (and our own unpublished
data) (Fig. 1a). The promoter of trap, encoding the
thrombospondin-related anonymous protein (TRAP), is
active from the late oocyst stage to the mature sporozo-
ites, but not in the liver stage [31]. In contrast, the uis4
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(upregulated in infectious sporozoites) gene is specific-
ally upregulated in infectious sporozoites, those resident
in the salivary glands of the mosquitoes and named ac-
cordingly [32–34]. Lastly, the lisp2 gene, encoding the
liver stage-specific protein 2, is expressed exclusively
during late liver stage development prior to formation of
infectious merozoites, the parasite forms infecting red
blood cells [35].
ZFN-mediated DSB requires binding of two ZFNs to
their respective 9–18 nucleotide long motif, followed by
the dimerization of the FokI endonuclease, which then
executes the DSB. We first generated a parasite line
expressing two well-characterised ZFNs (ZFNL and
ZFNR) shown to target the gene encoding the enhanced
green fluorescent protein (eGFP) [36]. In order to ex-
press the nucleases in the sporozoite stage, one of the
ZFNs was placed under the control of the csp promoter,
and the other under the control of the trap promoter
(Fig. 1b; Additional file 1). In addition to both ZFNs the
transfection plasmid also contained the gene encoding
the human dehydrofolate reductase (hDHFR) fused to
egfp. Both are under the control of the ef1α promoter
conferring resistance to pyrimethamine and thus allow-
ing selection for transgenic parasites at the blood stage;
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Fig. 1 Zinc-finger nuclease (ZFN)-mediated double-strand breaks (DSBs) and potential repair in the context of the Plasmodium life cycle. a Parts
of the life cycle relevant for this study with genome copy number of various stages indicated. Gene names of the used promoters are depicted
in red at the point of their respective activation. b Design of SpZFN and LsZFN transgenic parasite lines. Chr12a and Chr12b are the sequences
used for homologous integration into the genome. The selection marker hDHFR (human dihydrofolate reductase; yellow) is expressed as a fusion
protein with eGFP (enhanced green fluorescent protein; green) under the constitutively active ef1α promoter. The target sequence of the ZFNs is
present within the egfp gene. ZFNL and ZFNR are expressed under the control of the two promoters of csp and trap in SpZFN and the promoter
of lisp2 in LsZFN. Both zfn genes are fused with a 2A skip peptide (red) in LsZFN. c ZFN-induced DSB and possible post-DSB outcomes are
depicted. Homologous recombination (HR) can restore the original locus only if the genome copy number is >1 and restores ZFN binding sites,
since no sufficient homology regions are flanking the break site. Potential microhomology-mediated end joining (MMEJ) can repair the DSB,
resulting in small gene deletions that can be detected by loss of fluorescence. Parasites that fail to repair the DSB are expected to die
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the in-frame fusion of egfp to hdhfr provides the gen-
omic sequence targeted by the ZFNs. The plasmid
was integrated by double homologous crossover into
chromosome 12 of the P. berghei strain ANKA, where
integration of plasmids was shown not to interfere
with neighbouring gene function and DSB would re-
sult in the loss of many genes [37, 38]. The resulting
parasite line is here referred to as SpZFN. We ex-
pected that this would lead to ZFN expression during
sporozoite formation, thus causing a DSB in the egfp gene
and consequently in chromosome 12.
We also generated another parasite line expressing the
two ZFNs from the liver stage-specific lisp2 promoter,
termed LsZFN (Fig. 1b; Additional file 1). Here, both zfn
genes were separated by the self-cleaving 2A skip pep-
tide from Thosea asigna virus, which has been shown to
lead to efficient self-cleavage resulting in expression of
two genes in P. falciparum [28, 39]. We expected that
the ZFNs would be expressed in this parasite line during
late liver stage, leading to DSBs prior to the formation of
red blood cell-infecting merozoites.
We envisaged three possible outcomes following the
induced DSB (Fig. 1c). If a template of the original intact
locus is present in the nucleus, repair by HR could
occur, leading to parasites without genomic change.
This, however, would not only reconstitute the original
egfp gene but also the binding sites of the ZFNs and thus
likely lead to repeated DSBs. If no homologous repair
template is available, the DSB would lead to parasites
that lose a large proportion of the chromosome 12 arm
during cell division and subsequent cellularisation to
mature sporozoites or liver stage merozoites. In our case
this would lead to the loss of 847 kb and 231 annotated
genes. Of these, gene disruption has been attempted for
19 genes in P. berghei. Gene disruption was unsuccessful
with ten of these genes, suggesting that they are essential
in the blood stage (http://www.pberghei.eu). Our ZFN-
parasites would, therefore, likely not be viable, and fail
to establish blood-stage infections following injection of
salivary gland-derived sporozoites (Fig. 1a). With a lack
of NHEJ proteins, parasites might be able to repair the
DSB using alternative DNA repair mechanisms such as
microhomology-mediated end joining (MMEJ; Fig. 1c);
this has, however, never been observed in P. berghei.
Sterile protection through ZFN-mediated DSBs
After transfection of blood stage parasites and generation
of clonal lines that completed the asexual cycle normally,
we infected mosquitoes and challenged C57BL/6 mice
with various doses of sporozoites of both SpZFN and
LsZFN by intravenous (i.v.) injection (Table 1). All four
mice challenged with LsZFN, and 11 out of 43 mice chal-
lenged with SpZFN, developed blood-stage parasitaemia.
Only mice that did not develop a blood stage infection
were subsequently re-infected with SpZFN parasites fol-
lowing a classic prime-two boost scheme and challenged
with WT sporozoites. All fully immunised mice remained
blood stage-negative after challenge with 10,000 ANKA
WT sporozoites (Table 2). This shows that immunisations
using sporozoites attenuated through ZFN-mediated DSBs
in the sporozoite are possible and promote sterile protec-
tion. However, these data also showed that timing of the
ZFN-mediated DSBs is crucial to prevent breakthrough
infections.
Detection of genetic variation in parasites surviving
ZFN-mediated DSBs
The 15 parasite populations arising from the break-
through blood-stage infections were referred to as
"sporozoite induced" (SI) and given a respective number
(SpZFN SI 1–11, LsZFN SI 1–4). We first analysed these
parasites for eGFP expression using standard fluores-
cence microscopy with the aim to understand why 25 %
of infected SpZFN mice (11/43) and all LsZFN mice had
suffered from these blood-stage infections. We observed
a total of ten eGFP-expressing parasites (SpZFN SI 5–7,
9–11 and LsZFN SI 1–4), four non-fluorescent parasites
(SpZFN SI 1–4) as well as one with a mixed phenotype
(SpZFN SI 8) with half the parasites fluorescent and the
other half not.
Table 1 Summary of all mice challenged with sporozoites
Parasite line Sporozoite dose
injected i.v.
Infected mice/
total mice
Sporozoite-induced
breakthrough parasites
WT 10,000 4/4
WT 10,000 4/4
WT 10,000 4/4
SpZFN 10,000 0/4
SpZFN 25,000 1/10 SpZFN SI 1
SpZFN 25,000 3/9 SPZFN SI 2–4
SpZFN 500,000 4/4 SpZFN SI 5–8
SpZFN 25,000 3/16 SpZFN SI 9–11
LsZFN 10,000 4/4 LsZFN SI 1–4
Sp2ZFN 25,000 0/4
Sp2ZFN 10,000 0/4
Ls2ZFN 25,000 5/12 Ls2ZFN SI 1–5
Ls2ZFN 250,000 4/8 LsZFN SI 6–9
Ls2ZFN 1,000,000 2/4
Uis4ZFN 25,000 0/8
Uis4ZFN 250,000 3/8 Uis4ZFN SI 1–3
TrapZFN 25,000 2/4 TrapZFN SI 1–2
TrapZFN 250,000 0/4
SpZFN SI 2 10,000 8/8
SI sporozoite induced
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We next genotyped these breakthrough parasites by
PCR and sequencing of the egfp gene as well as the locus
spanning both zfn genes (Fig. 2). We found that PCR
across both zfn genes from the genomic DNA (gDNA)
of blood-stage SpZFN resulted in an amplicon of the ex-
pected full-length (pre-DSB) size of 4184 bp, but also
detected an additional, shorter PCR product. For SpZFN
SI 1–4 only the full-length product was observed;
SpZFN SI 5–11, on the other hand, exclusively amplified
the smaller product. Sequencing of this amplicon
showed that all these parasite lines had reduced their zfn
copy number resulting in a hybrid between zfnL and
zfnR using different regions of perfect homology be-
tween the two genes, ranging from 57–333 bp (Fig. 2b).
As ZFNL and ZFNR utilize two slightly mutated FokI
domains to optimise formation of heterodimers and
avoid formation of homodimers [40], reduction to a
single zfn renders them non-functional, independent of
their DNA binding motifs. We observed the same result
for LsZFN SI 1, 3 and 4 as well.
All SpZFN parasites that retained both zfn genes in
the genome showed a modification in the egfp gene,
resulting in the loss of the binding sites of both ZFNs.
SpZFN SI 1–4 all presented the same 75-bp deletion,
originally flanked by the 6-bp microhomology region
GCCGAC. One subpopulation of SpZFN SI 8 (c1) had
lost 81 bp that were originally flanked by the 7-bp region
AGGAGAA. Since only 11 out of 43 mice challenged
with SpZFN developed blood-stage parasitaemia, we
postulate that all but SpZFN SI 8 are clonal populations.
All of these have either produced a single hybrid zfn or
carry a deletion in the egfp gene covering the ZFN bind-
ing sites, thus preventing DSBs to occur.
The sequencing of egfp and zfn loci was consistent
with our fluorescence microscopy observations: those
populations that had a single recombined zfn copy
retained an intact egfp and were fluorescent, while all
non-fluorescent parasite lines had gone through recom-
bination events within the egfp gene and retained an in-
tact zfn locus.
These PCR data also showed that the gfp locus was
intact in the parental clones, i.e. those parasites that
were transmitted to the mosquitoes. However, reduction
(as well as expansion) of zfn copy number from two to
one on the other hand had already occurred at a low fre-
quency during asexual growth of the parasite and could
be detected in the SpZFN but not the LsZFN clone. This
phenomenon was observed in the past with reversion
of genetic modifications based on a single crossover
in P. berghei that introduces homologous regions in
close proximity within a few thousand base pairs [41].
The same mechanism is routinely used for genetic
modification of malaria parasites during the removal
of a negative selection marker of plasmids already in-
tegrated by single or double crossover in P. falcip-
arum and P. berghei, respectively. It was also found
that copy number variations in resistance loci most
likely occur using non-allelic homologous replication
or single strand annealing [23, 42].
LsZFN SI 2 had no modification in the zfn and egfp
genes, suggesting that the expression of the ZFNs late
during the liver stage might leave insufficient time for an
efficient DSB to be produced before merozoite formation.
Thus, merozoites could form that had not undergone a
DSB. Alternatively, excess templates for continuous HR
might be present in the liver stage due to the many copies
available within one nucleus. Sequencing of the lisp2 pro-
moter region confirmed no mutations [35].
To test if SI parasites suffered from reduced fitness, we
used SpZFN SI 2 to re-infect mice and mosquitoes and
analysed its growth and infectivity across the life cycle in
comparison with WT parasites (Additional file 2; Tables 1
and 3). After i.v. injection of 10,000 sporozoites as well as
mosquito infection by bite, SpZFN SI 2 caused compar-
able blood-stage growth and experimental cerebral mal-
aria as ANKA WT parasites. This revealed no difference
and hence suggests that expression of the ZFNs does not
impede parasite fitness.
Improved second generation of ZFN parasites to reduce
breakthrough rates
The experiments described above suggest that the skip
peptide works in P. berghei as in P. falciparum, thus
allowing expression of both ZFNs from a single pro-
moter. They also clearly imply that modification of the
coding sequence of one of the two zfn genes is required
Table 2 Protection of immunised mice against P. berghei ANKA WT challenge
Parasite line Sporozoite dose i.v. for immunisation Number of boosts Mice positive after WT challenge Prepatency after challenge (days)
SpZFN 10,000 2 0/4 NA
SpZFN 25,000 2 0/18 NA
Sp2ZFN 25,000 2 2/4 5.5
Sp2ZFN 10,000 2 1/4 7
Ls2ZFN 25,000 2 0/7 NA
Ls2ZFN 250,000 0 4/4 5.5
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to maintain both nucleases in the genome and prevent
HR between the two genes. Based on these findings of
the first generation of ZFN-expressing parasites, we de-
signed two new parasite lines Sp2ZFN and Ls2ZFN
(Fig. 3a). Those expressed both ZFNs under the control
of the csp or lisp2 promoter, respectively, separated by
the 2A skip peptide. To avoid HR between both zfn
genes, we codon-modified zfnL to zfnLcm to have the
lowest possible homology with zfnR. This was accom-
plished by first codon-optimizing zfnL for P. berghei
codon usage [43, 44] and then manually changing all co-
dons still identical to zfnR whenever possible (Additional
file 3). Additionally, we introduced a silent point mu-
tation within the 6-bp homology of egfp that had
been utilised to resolve the DSB in SpZFN SI 1–4,
generating mgfp.
While both parasite lines showed no phenotypic differ-
ence to WT parasites prior to sporozoite formation,
sporozoite numbers of Sp2ZFN were strongly reduced in
the salivary gland (Table 3). This limited the number of
experiments we could perform and also rendered this
parasite line non-practical for use as an attenuated para-
site line in large-scale vaccination experiments. Add-
itionally, not all mice immunised with Sp2ZFN showed
sterile protection after challenge with 10,000 P. berghei
ANKA WT sporozoites (Table 2), which is in agreement
with the early liver stage arrest we observed in an in
vitro liver stage development assay (Additional file 4).
Challenge of C57BL/6 mice with Sp2ZFN and Ls2ZFN
parasites resulted in either a block of parasite develop-
ment (all Sp2ZFN and some Ls2ZFN) or the emergence
of blood-stage parasites. The latter populations were
termed Ls2ZFN SI 1–9. Of the parasites derived from
Ls2ZFN challenge, Ls2ZFN SI 1, 2, 4–9 showed GFP ex-
pression whereas Ls2ZFN SI 3 was non-fluorescent. We
genotyped all parasite lines by PCR and sequencing
(Fig. 3) and found no modifications of the ZFN locus,
validating the improved genetic stability resulting from
our codon-modification approach. In Ls2ZFN SI 3 para-
sites, however, we observed an 81-bp deletion within
mgfp that includes the ZFN binding sites, originally
flanked by the 4-bp microhomology CATC. All other SI
blood-stage parasites showed no genetic modification
and most likely escaped DSB by HR or non-timely ZFN
expression.
Optimisation of ZFN expression timing
The experiments with the second generation of parasites
suggested that timing of ZFN expression was either too
early (Sp2ZFN) or too late (Ls2ZFN). We therefore
aimed to identify optimal promoters that are driving ex-
pression either late during sporozoite formation or once
sporozoites are formed. In SpZFN, the trap promoter
mainly determined the timing of DSB, as it becomes
(See figure on previous page.)
Fig. 2 Genotype analysis of parasites surviving ZFN-induced DSB. a PCR analysis of the zfn (P1 P2) and egfp (P3 P4) loci from genomic DNA of
blood-stage parasites. The generated transgenic clone (c1) and parasite populations from mice positive after sporozoite challenge were analyzed.
Expected sizes of the PCR products are 4184 bp for SpZFN, 3475 bp for LsZFN and 837 bp for egfp. The PCR product size from the ZFN locus was
smaller in SpZFN SI 5–11 and LsZFN SI 1, 3 and 4. The egfp product was slightly smaller in SpZFN SI 1–4 and two products are observed in SpZFN
SI 8. b Schematic alignment of the genomic sequences obtained from all zfn loci with size varying from original clones. The boundaries
of homology regions used for gene copy number reduction are depicted for both zfnL and zfnR. The range of perfect homology used
for recombination is indicated. c Alignment of the sequenced egfp gene of all parasite lines. Binding sites of ZFNs are coloured in the
first sequence and all others if present. Microhomology regions implicated in repair are highlighted in colour and with a red background
in those sequences that have undergone repair. Note that SpZFN SI 8 was a mixed population that differed in the egfp gene from the other populations
that underwent repair. d Overview of the detected genomic changes of all SI parasites. Note that all have either a modification of the zfn locus or of the
egfp gene with the exception of LsZFN SI 2, which survived without any genetic changes. Positions of primers used for PCR are indicated
Table 3 Infectivity of parasite strains in Anopheles stephensi
Parasite line Midgut sporozoites/
mosquito
Salivary gland sporozoites/
mosquito
Salivary gland sporozoites/
midgut sporozoites
Number of infected mosquitoes
analysed
WT 111,000 21,000 0.19 30
SpZFN 84,000 12,000 0.14 18
LsZFN 157,000 29,000 0.18 22
Sp2ZFN 50,000 2500 0.05 30
Ls2ZFN 181,000 22,000 0.12 30
Uis4ZFN 5300 1700 0.32 14
TrapZFN 55,000 25,000 0.46 11
SpZFN SI 2 17,000 8300 0.49 30
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active after the csp promoter. We thus argued that using
this promoter instead of the stronger and earlier csp
promoter should result in more viable sporozoites
and hence generated the respective parasites, termed
TrapZFN. We also speculated that a slightly later
induction of DSB within the salivary gland might be
even more beneficial, as all sporozoites contain only a
single copy of the genome. Additionally, DNA repair
proteins might be down-regulated in the sporozoite
stage compared with the actively dividing oocyst. We
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Fig. 3 Improved second generation of ZFN parasites and genotyping of resultant SI populations. a Design of Sp2ZFN and Ls2ZFN. zfnLcm (blue)
is a codon-modified version of zfnL to maximise codon difference between zfnL and zfnR (grey). Sp2ZFN and Ls2ZFN drive expression of both
ZFNs fused by the 2A skip peptide (red) from a single promoter. The mgfp (green) is a codon-modified version of egfp that carries a silent mutation
within the most frequently observed microhomology in SpZFN SI (Fig. 2c). b PCR amplicons of ZFN loci and the mgfp gene are shown for Sp2ZFN c1
as well as Ls2ZFN c1 and LsZFN SI 1–9. Expected sizes are 3091 bp and 3479 bp for ZFN loci in Sp2ZFN and Ls2ZFN, respectively. Expected size of mgfp
is 837 bp. Only Ls2ZFN SI 3 showed a slightly smaller size for mgfp. c Alignment of all mgfp genes. Only Ls2ZFN SI 3 showed a deletion of 81 bp.
Binding sites of ZFNs are shown in colour if present. The microhomology region of 4 bp implicated in repair is highlighted in colour and with a red
background. d Overview of the genomic loci found in all Ls2ZFN SI parasites. Only Ls2ZFN SI 3 is changed in respect to the original clone Ls2ZFN c1.
No SI parasites were observed for Sp2ZFN
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thus selected the uis4 promoter, which is active only
once sporozoites are within the salivary gland. The
generated parasite line using this promoter was called
Uis4ZFN (Fig. 4a). As expected, both parasite lines
showed an increased salivary gland to midgut ratio
compared with Sp2ZFN (Table 3) and an intermediate
development in HepG2 cells compared with Sp2ZFN
and Ls2ZFN (Additional file 4).
We then injected mice with 25,000 and 250,0000 spo-
rozoites of each of the two lines. Eight mice injected
with a total of 1.1 million TrapZFN sporozoites resulted
in TrapZFN SI 1–2, whereas 16 mice injected with 2.2
million sporozoites of Uis4ZFN resulted in Uis4ZFN SI
1–3 (Table 1), all non-fluorescent. Genotyping of the SI
parasite TrapZFN and Uis4ZFN populations showed that
they contained the unmodified ZFN locus (Fig. 4b),
again confirming that the use of codon-modified ZFNs
prevented unwanted recombination events. However,
TrapZFN SI 1 had a deletion of 369 bp within mgfp
originally flanked by the microhomology sequence
CGGCA, and TrapZFN SI 2 showed a loss of 474 bp
originally flanked by the sequence CGGCGA (Fig. 4b, c;
Additional file 5). Genotyping of Uis4ZFN SI 1–3 re-
vealed the same 81-bp deletion for all three clones
flanked by 10 bp of microhomology; however, this
sequence contained a single mismatch (Fig. 4b, c;
Additional file 5). This curious result suggests that
MMEJ resulted in a single mismatch that was toler-
ated and gave rise to two populations during the fol-
lowing mitotic divisions leading to sporozoite
formation. As these three clones have been isolated
from three individual mice, it is more likely that the
DSB occurred in the oocyst before sporozoite forma-
tion and not as three independent DSBs in salivary
gland sporozoites being repaired with the same
10 bp of microhomology. Thus, we expect that at
least in one oocyst, the uis4 promoter was active
and not, as expected, silent until the salivary gland
sporozoite stage.
Sequence determinants for MMEJ
Having identified seven different MMEJ events in 11
parasite lines we tried to identify whether they shared
potential requirements for homology regions utilized
during DNA repair (Additional file 5). The average GC
content of the homology regions used for repair was
68 % compared with 62 % within the entire egfp. We
would expect that the amount and length of possible
homology regions might increase within the AT-rich
intergenic regions in Plasmodium but that high GC con-
tent should favour stronger binding. A computationally
scrambled DNA sequence of 1000 bp with a GC content
of 20 % contained 91 homology regions of at least 8 bp,
whereas the 795 bp long open reading frame of egfp still
contained 77 homology regions of at least 7 bp in length.
This implies that the parasite can potentially repair a
DSB at every genomic location, but frequencies of repair
are low and depend on the life stage timing of DSB.
Analysis of chromosomal integrity of parasites failing to
repair the DSB
So far, all our analysis concerned the few parasites that
managed to survive their experimentally designated fate.
However, we also aimed to analyse the main populations
of parasites that failed to resolve the DSB and did not
progress through the life cycle. In order to do so we
opted for quantitative PCR (qPCR) analysis of genes
located at either side of the DSB. This approach
would also allow us to effectively quantify the effi-
ciency of ZFN activity in the parasite. We extracted
genomic DNA from original blood-stage parasites (BS),
infected mosquito midguts 10 days post-infection (MG)
and from infected salivary glands 17 days post-infection
(SG). We designed primes to amplify short (131–216 bp)
DNA fragments on either side of the egfp gene as
well as spanning the egfp ZFN binding site (Fig. 5a).
As a control we chose primer pairs to amplify genes
from chromosome 13.
Measurement of the relative gene copy number
showed the presence of all DNA fragments within all
parasite lines (Additional file 6). We combined the data
for the left part of chromosome 12 lacking the centro-
mere (with respect to the cutting site) and the right part
of chromosome 12 that contains the centromere. The
ratio of SG to MG shows the relative copy number of
both sides that is retained in salivary gland sporozoites
(Fig. 5b). Parasite lines expressing the ZFNs within the
oocyst (SpZFN, Sp2ZFN and TrapZFN) showed a strong
reduction in the relative copy number of the left part of
chromosome 12 but not the right part. Uis4ZFN as well
as Ls2ZFN, on the other hand, retained both parts of
chromosome 12 in the salivary gland. This was inde-
pendent of the occurrence of the DSB, as revealed by
the qPCR signal across the cutting site. This PCR prod-
uct can only be produced if the egfp is still uncut; it was
already very low for Uis4ZFN in the salivary gland but
still high in Ls2ZFN parasites, which did not express the
ZFNs yet (Fig. 5c). These results indicate that it is not
the DSB itself that causes the developmental defect and
that cell division is not arrested after the DSB. They also
suggest that as soon as nuclear division takes place the
centromere-devoid part of the chromosome is lost.
Discussion
Here we show that ZFNs can be used to generate atten-
uated P. berghei parasites with a single DSB. Parasites
with an unresolved DSB lose their centromere-lacking
half of the broken chromosome during the next cell
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Fig. 4 ZFN parasites with optimised expression timing and genotyping of SI populations. a Design of TrapZFN and Uis4ZFN. Both parasite lines
express ZFNs fused with a 2A skip peptide under control of the respective promoters of trap and uis4. b PCR products of the zfn loci and the
mgfp gene are shown for parental clones Uis4ZFN c1 and Uis4ZFN SI 1–3 and TrapZFN c1 as well as TrapZFN SI 1–2. The expected size of the zfn
genes was 3303 bp for Uis4ZFN, 3321 bp for TrapZFN and 837 bp for mgfp. The ZFN loci were all identical in size, whereas Uis4ZFN SI
1–3 and TrapZFN SI 1–2 showed shorter PCR products for mgfp of varying sizes. c Alignment of all mgfp genes. TrapZFN SI 1 had a
deletion of 369 bp; in TrapZFN SI 2 474 bp were deleted. Binding sites of ZFNs are coloured and the microhomology regions implicated
in repair of 6 and 7 bp, respectively, are highlighted in colour and with a red background. Both Uis4ZFN SI 1–2 and SI 3 had a deletion
of the same 81 bp. Microhomology regions implicated in repair are 10 bp, including one mismatch highlighted in white for SI 1–2 and
7 bp for SI 3. d Overview of the genomic loci found in both TrapZFN SI 1–2 and Uis4ZFN SI 1–3. Both TrapZFN SI parasites have big
deletions in the mgfp gene with respect to the original clone TrapZFN c1; Uis4ZFN SI parasites show a small deletion in the mgfp gene
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division, resulting in the loss of hundreds of genes.
When the DSB is correctly timed, sporozoites can still
invade liver cells but arrest in development and are un-
able to produce blood-stage infections. Immunisation
with some of these parasites results in a sterile protection
that is comparable to traditional GAPs. This, together
with the data from all previous GAP immunisation
studies, hints to the fact that parasites arresting within
the liver always confer protective immunity from subse-
quent challenges with WT parasites. This appears inde-
pendent from the cause of arrest [45], although subtle
differences in protective efficacy can be observed [46].
In follow-up studies it will be interesting to observe
potential differences between ZFN-mediated and classic
GAP parasites, especially when ZFNs are expressed in
different loci (Fig. 6).
The deletion of a single GAP candidate gene fre-
quently results in breakthrough infections in the experi-
mental mouse host. Although originating from a clonal
population, a few mutant parasites often manage to sur-
vive in the absence of a particular protein [16]. The
dearth of gene expression data for liver stages of human
malaria parasites impedes the rational choice of GAP
target genes. Also, transfer of experimental data from
the rodent model parasites to P. falciparum has not been
straightforward [21]. This is likely due to the nature of
the liver stage. In contrast to motile stages that exhibit
many essential stage-specific genes, liver stage-essential
genes can be broadly grouped into two subsets. Genes
involved in growth and cell division are mainly shared
with the blood stage and thus are not suitable for GAPs
as their deletion is often not possible. Other genes are
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Fig. 5 Copy number analysis by qPCR on genomic DNA. a Schematic overview of chromosomes 12 and 13. The centromere of chromosome 12
is shown in red. Binding sites for primer pairs used for qPCR are shown. Primer pair C1 amplifies the product over the cutting site of the ZFNs,
while primer pairs L1 and R1 bind approximately 100 kb away from the telomeres on the left and right arm of chromosome 12, respectively. L2
and R2 bind around 8 kb away from the cutting site. N1 and N2 bind on the ‘control’ chromosome 13 and are used for normalization. b The
ratio of the relative copy number of amplicons from both sides of the break point on chromosome 12 (L1 and L2 on left of break; R1 and R2 on
right of break) is shown for parasites isolated from mosquito salivary glands (SG) compared with parasites isolated from midguts (MG). The copy
number of the left side of chromosome 12 is strongly reduced in the SG sample for parasites expressing ZFNs in the midgut, whereas the right
side is not affected. All individual values, including errors, are shown in Additional file 6. c The relative copy number of PCR products amplified
over the break point shown for genomic DNA isolated from midgut oocysts (MG) and from salivary gland sporozoites (SG). Note the near
absence of product in salivary glands from parasites where ZFNs are expressed before (SpZFN, TrapZFN) or during (Uis4ZFN) sporozoite entry into
salivary glands. Positive and negative error is calculated from standard error of the mean from technical duplicates
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involved in host–pathogen interaction. These genes are
part of the evolutionary battle between the parasite and
its host cell. Here, a shifted balance in favour of the host
cell after gene deletion might be partially reversed if
additional diseases or environmental factors affect the
host, thus causing breakthrough infections. This is not
an issue in ZFN-induced DSB as survival will only de-
pend on the repair capabilities of the parasites and not
be affected by the host cell.
For traditional GAPs, breakthrough infections are not
genetically tractable as they are not a product of genetic
modification. In contrast, here we could analyse the rea-
son for parasite survival in our ZFN-induced DSB-
mediated GAPs. We found two ways by which parasites
escaped their designated fate. The first utilized an inher-
ent property in the design of ZFNs, which are long
stretches of identical coding regions shared by the two
ZFNs. Parasites used these homologies to loop out the
region in-between the ZFNs during blood-stage growth.
We assume that this might be induced by a random
DSB [23]. HR utilising close/adjacent homologous re-
gions of several hundred base pairs in length has been
observed sporadically [47]. Indeed, this mechanism is
routinely relied upon in negative selection approaches
that allow sequential genetic modification in the absence
of multiple selection markers as only two positive selec-
tion markers are used in P. berghei research [42]. Our
work addresses the molecular requirements behind the
phenomenon of recombination in P. berghei. We found
recombination events based on large-sized homology re-
gions in the ZFN coding regions akin to experimental
negative selection. This occurred more frequently in
LsZFN where the zfn genes are closer to each other than
in SpZFN. This suggests that the distance between hom-
ology regions might increase the likelihood of recombin-
ation. In the case of SpZFN, to generate sporozoites
Fig. 6 Current and potential future liver stage attenuated parasites. GAP parasites are generated by the deletion of a gene of interest (GOI)
essential for the Plasmodium liver stage. While this leads to developmental arrest in the liver in most cases, rare breakthrough events are
observed. The frequency depends on the GOI, and how single parasites survive is not understood. ZFN arrested parasites described in this
manuscript arrest as they lose the arm of the chromosome lacking the centromere after DSB. Rare breakthrough events are the result of DSB
repair via MMEJ and result in loss of the ZFN target site. Potential future approaches include the combination of GAPs with ZFNs. A single
genetic modification allows for the replacement of a GOI with a ZFN construct. These parasites have to overcome both the DSB via MMEJ and
the missing gene to result in a breakthrough infection. However, the localisation of the GOI on the chromosome influences the number of genes
lost after DSB and thus possibly attenuation. Another potential approach is the use of a nuclease to target conserved sites in a subtelomeric
multi-gene family (Additional file 7). This leads to multiple DSBs, resulting mainly in the loss of telomeres. Developmental arrest might be delayed.
Potential repair can occur via MMEJ, resulting in the loss of the target site or via HR restoring the target site. Centromeres are drawn in red, DSBs
are depicted with a gap, dashed arrows mark rare events
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with only one zfn, both parasites must have reduced the
locus before they form the zygote since the parasite will
remain diploid until sporozoite formation (Fig. 1a). In
the case of LsZFN, only the single haploid genome copy
of the sporozoite invading the liver cell must have had
its copy number reduced before invasion. We also
showed that such recombination can be prevented by
codon modifications to avoid any homology within the
recombination-prone sequence (Additional file 3). These
observations also led us to consider why there have been
no reports on the successful use of TALENs (transcrip-
tion activator-like effector nucleases) in Plasmodium
until now. Given that the central repeat domain contains
18–20 repeats coding for 33–34 amino acids each and
only differing by a few base pairs, we would suggest that
TALENs might reduce their number of repeats within
the parasite [48].
More importantly, parasites could survive a DSB by re-
pair that was found to proceed with as little as 4-bp
homologies. In the seven different repair products we
observed, we found 4–10-bp homologies with up to one
mismatch, deletions of 75–474 bp, and no insertions
(Additional file 5). These repair events have the character-
istics of MMEJ, which is defined by homology of 5–25 bp
and the deletion of the previously flanked sequence [49].
These events are most likely extremely rare; an estimation
based on the number of SI clones observed during the im-
munisation protocol suggests about one survivor out of
50,000–700,000 initially injected parasites. Comparison of
these breakthrough rates within the ZFN parasites and
with published GAPs is not straightforward, mainly due to
sporozoite doses used in the various studies. In our lim-
ited sample size of breakthrough mice we found a very
weak correlation of chance for breakthrough with the
number of parasites injected for Ls2ZFN, a good correl-
ation for Uis4ZFN and an inverse correlation for
TrapZFN (Table 1). This would predict that the injection
of, for example, 100 mice with 25,000 sporozoites each
would result in a different number of breakthrough events
than the injection of 5 mice with 500,000 sporozoites
each. Published breakthrough rates range between one
out of two mice for uis4(−) [50] and non at all for
fabb/f(−) [17]. This suggests that our ZFN parasites
fall within that range. Without the selection of
mutants that lose the ZFN cutting site, this small
population of mutants would not have been observ-
able. As the numbers of breakthrough infections var-
ied strongly between parasite strains and experiments,
we expect them to be influenced by the exact timing
of the DSB. Of the parasite lines tested, we would
favour Uis4ZFN and TrapZFN for future experiments.
While Uis4ZFN has the advantage that the main
expression of the zfn genes only starts in the salivary
gland, TrapZFN stops zfn expression in the liver
stage, which could be favourable in terms of applica-
tion safety if this system is applied to P. falciparum.
Of more than 12.5 million sporozoites injected in this
study, no parasite managed to survive with a mutation
in zfn genes or with the DSB once it occurred and part
of chromosome 12 was lost. The latter parasites did ar-
rest most likely due to loss of multiple genes as well as
chromosomal instability due to telomere loss.
Another study in P. falciparum, utilizing a Sce-I-
induced DSB, also observed end joining repair products
in the absence of homologous templates [27]. In contrast
to our findings, Kirkman et al. [27] observed repair inde-
pendent of obvious microhomologies and a maximal loss
of 5 bp in combination with a 2 bp insertion. While this
might hint at a different mechanism of repair, the ob-
served rate of repair was similarly inefficient to the one
observed in our experiments. The different outcomes of
repair might not, therefore, necessarily rely on different
mechanisms of DNA repair between P. berghei and P.
falciparum but could be due to the different ends cre-
ated by the Sce-I and ZFNs. Also, the observed repair
occurs in different stages of the life cycle, as the study
by Kirkman and colleagues was performed in the blood
stage. Thus, we cannot exclude that the different stages
might influence the expression of proteins involved in
DNA repair pathways. In this respect, it is also worth
noting that microhomology pairing in blood-stage
parasites occurs at 37 °C but only at 21 °C in mosquitoes.
Possible differences could be tested by expressing Sce-I in
P. berghei sporozoites in a similar fashion as we expressed
the ZFNs.
MMEJ has been shown to require six key proteins in
mammals: MRE11, NBS1, LIGASE III, XRCC1, FEN1
and PARP1 [51]. Of these, only MRE11, XRCC1 and
FEN1 have been identified in Plasmodium, and MRE11
has recently been characterised in P. falciparum [52].
Of those missing, DNA ligase III seems to be replace-
able by DNA ligase I [53] and PARP1 is only present
in the related parasite T. gondii, supporting its sug-
gested role to compete with Ku for choice of repair
pathway [54]. NBS1 is only present in eukaryota and
seems to be the least conserved part or the MRN
complex, which otherwise consists of MRE11 and
RAD50, which are also conserved in bacteria and ar-
chaea [55]. NBS1 shows no sequence homology with
its functional homolog in Saccharomyces cerevisiae,
XRS2. This makes identification of a homolog in Plas-
modium via homology searches unlikely. Very recently,
the human polymerase θ was identified to promote
alternative NHEJ and suppress homology-dependent
repair [56, 57]. We identified a potential homolog in
P. berghei [GenBank:CDS50785.1; PBANKA_134600].
If any of those factors are essential for MMEJ but not
for life cycle progression in Plasmodium, their deletion
Singer et al. Genome Biology  (2015) 16:249 Page 13 of 18
could be combined with the ZFN parasites to abrogate
MMEJ repair after DSB.
The use of ZFN allows the simultaneous deletion of
tens to hundreds of genes for the generation of attenu-
ated parasites. Our work is a proof-of-principle using
only a single cleavage site within the entire genome. This
suggests that the inclusion of several more cleavage sites
should prevent any breakthrough infections. Such add-
itional targets could either be introduced throughout the
genome experimentally (as shown in this work) or rely
on endogenous sequences. The latter approach could
most easily be established by targeting conserved gen-
omic regions that are present in multi-gene families,
such as bir in P. berghei, yir in P. yoelii, or var in P.
falciparum. While this could be achieved with ZFNs, it
could also be tested by utilising CAS9 [58], as shown for
multi-copy genes in Trypansoma cruzi, the causative
agent of Chagas disease [59]. These approaches should
result in telomere loss and slow decline of the parasite
population instead of immediate arrest, which could be
beneficial for the generation of attenuated parasites.
Deletion of P. berghei telomere reverse transcriptase has
been performed and resulted in a delayed death pheno-
type [60]. We found up to 104 targets with a single tar-
get site in the bir gene family, 522 in the yir gene family
and up to 39 for the var gene family (Additional file 7).
This strategy has two potential Achilles heels: a single
mutation in the nuclease could result in a loss of func-
tion resulting in breakthrough; additionally, multiple tar-
get sites will not all be cut at once, so besides MMEJ the
parasite could also utilize HR to repair the DSB. Ultim-
ately, genetically attenuated parasites will have to be
generated from a combination of multiple “arresting
phenotypes”. This is the current rationale for deleting
multiple genes involved in different parasitic mecha-
nisms or pathways [22, 61]. Hence, a nuclease-based
method can easily be combined with a single gene
knockout by introducing the ZFN cassette into the locus
of a GAP candidate gene during the generation of that
GAP parasite (Fig. 6). Since timing of expression can be
easily changed for ZFN-induced DSB, it should be pos-
sible to combine multiple arrested phenotypes to arrest
at the same time. Change of localisation of the DSB into
the locus of a GAP candidate gene will influence the
genes that are lost after the DSB. In the case of subtelo-
meric localisation, this could reduce the promptness of
arrest, but ultimately should result in death of the para-
site due to genome instability. We have summarised
genetic attenuation strategies tested so far and compared
them with the suggested strategies in Fig. 6.
Conclusions
Here we probed the suitability of ZFN-induced DSBs to in-
vestigate DNA repair mechanisms and for the generation
of attenuated parasite lines in a rodent malaria parasite spe-
cies. Our data show clearly that Plasmodium can repair, at
low frequency, DSBs using MMEJ. We could also show that
attenuated parasite lines can be generated for use in experi-
mental vaccination studies and provide a rationale for mov-
ing these forward towards generation of safe attenuated
parasite strains for potential use in clinical studies.
Materials and methods
Animal work
All animal experiments were performed according to the
FELASA and GV-SOLAS standard guidelines and were ap-
proved by the German authorities (Regierungspräsidium
Karlsruhe). Experiments to generate parasite lines and
infect mosquitoes were performed with NMRI mice
and parasites involving sporozoite injections were per-
formed with female C57BL/6 mice (both from Charles
River).
Plasmid generation
All vectors used for this study were derived from Pb237
[38]. The following modifications were made. A 565-bp
upstream region of ef1α was amplified from P. berghei
ANKA WT gDNA with P5/P6 (Additional file 8) and
cloned with AgeI/ApaI to replace the promoter sequence
driving the selection marker. The hdhfr gene was ampli-
fied from human cDNA with P7/P8 and cloned with
AgeI/NheI. Next egfp was amplified with P9/P10 and
cloned upstream in frame with hdhfr with AgeI to result
in an egfp-hdhfr fusion gene (Pb238). To generate the
expression box for the ZFNs, subcloning was per-
formed in pGEM. The promoter of CSP was ampli-
fied with P11/P12 and cloned into pGEM. zfnL was
amplified with P13/P14 and inserted with KpnI/PshAI,
followed by insertion of the 3’ UTR of csp (P15/P16)
with PshAI/SwaI. In parallel, the fragments of the 3’
UTR of dhfs, zfnR and TRAP promoter were ampli-
fied with P17/P18, P19/20 and P21/P22, respectively,
cloned into pGEM with direct ligation, PshAI/KpnI
and SwaI/PshAI, and cloned with EcoRV/SwaI into
the first pGEM vector. The whole fragment was
cloned with NotI/EvoRV into Pb238, resulting in the
vector SpZFN. To generate LsZFN, the promoter of
lisp2 was amplified with P23/P24, zfnL was amplified
with P25/P26, introducing the 2A skip peptide via
P26. Both PCR products were fused with overlap ex-
tension PCR using P23/P26 and cloned into SpZFN
with NotI/PshAI.
To generate mgfp for the following vectors, two frag-
ments of egfp were amplified with P27/P28 and P29/P30,
fused with overlap extension PCR P27/P30 and cloned
into LsZFN with SwaI/PstI. The zfnL gene was codon-
modified with the codon usage table from P. berghei
(http://www.kazusa.or.jp/codon/) [43] that was applied
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with OPTIMIZER (http://genomes.urv.es/OPTIMIZER/)
[44]. The resulting coding sequence was aligned with
zfnR and in all identical codons a silent mutation was
introduced wherever possible, resulting in an additional
21 bp changed. The resulting sequence, zfnLcm with
fused 2A skip peptide, was ordered from GeneArt
(Regensburg). The promoter of csp/lisp2 was amplified
with P31/P32 and P33/P34, cloned via NotI/HindIII
into zfnLcm and together with zfnLcm cloned into
LsZFN (mgfp) with NotI PshAI, resulting in Sp2ZFN
and Ls2ZFN, respectively. To generate TrapZFN and
Uis4ZFN, the respective promoter regions were amp-
lified with P35/P36 and P37/P38, and cloned with
NotI/NdeI into Sp2ZFN.
Parasite transfection and sporozoite generation
Transfection was essentially performed as published
[62]. All vectors were linearised with PvuI prior to trans-
fection and integrated into chromosome 12 between
bases 846,483 and 847,711 using two homology regions,
Chr12a and Chr12b, with lengths of 481 and 431 bp, re-
spectively. All parasite lines were generated by a single
transfection. PCR to confirm correct integration was
performed after transfection and after limiting dilution
cloning (Additional file 1). Anopheles stephensi mosqui-
toes were infected with clonal lines as described previ-
ously [63].
Immunisation
Mice were immunised with SpZFN, Sp2ZFN and
Ls2ZFN sporozoites. C57BL/6 mice were injected i.v.
with sporozoites in RPMI medium. Immunisation was
performed with three injections, one prime and two
boosts. The time after injection until the next boost and
the challenge with ANKA WT sporozoites was 14, 7 and
7 days for 10,000 SpZFN sporozoites for 4 mice and with
25,000 sporozoites for 13 mice. All other immunisations
were performed with gaps of 14, 7 and 14 days. Mice
challenged after single dose immunisations were chal-
lenged 35 days after prime (Table 2).
PCR analysis and sequencing
All parasites that managed to result in blood-stage para-
sites after blood-stage challenge (SI) were analysed with
PCR. The zfn locus was amplified with P1(Sp/Ls/Uis4/
Trap)/P2 and egfp/mgfp was amplified with P3/P4. Add-
itionally, promoter sequences of LsZFN and Ls2ZFN SI
parasites lacking any modification in zfn and egfp/mgfp
were amplified with P53/P34 and sequenced. PCR prod-
ucts were purified and sequenced at GATC (Konstanz).
Quantitative PCR
We purified gDNA from midguts 10 days post-infection
(MG) and salivary glands 17 days post-infection (SG)
and mixed blood stages (BS). When possible, 200,000
sporozoites were used for gDNA production. Primers for
qPCR were chosen to amplify a product over the cutting
site C1 (P39/P40), 8133 bp upstream of the cutting site
L2 (P41/P42) and 8240 bp downstream of the cutting
site R2 (P43/P44). Additional probes were designed
100 kb away from the telomere upstream L1 (P45/46)
and downstream R1 (P47/P48) of the cutting site. Probes
for normalisation were designed for chromosome 13, N1
(P49/P50) and N2 (P51/P52). qPCR was performed with
SYBR Green PCR master mix (Life Technologies) on
an ABI7500 thermo cycler (Applied Biosystems) with
40 cycles of 15 s denaturation at 95 °C and 1 min at
60 °C. Reactions were performed in 12.5 μl final vol-
ume in technical duplicates. Fold differences of SG
and MG samples relative to BS samples were calcu-
lated according to the 2ΔΔCT method, using N1 and
N2 as housekeeping loci.
Microscopy
Imaging was performed with an inverted Axiovert
200 M microscope from Zeiss (Jena). Live blood stages
were imaged with a GFP filter set and differential inter-
ference contrast. Liver stages were fixed after 48 h with
4 % paraformaldehyde for 15 min, stained with α-CSP
(mAB 3D11) or α-UIS4 antibody and α-GFP antibody
Abfinity™ from Life Technologies. Image processing and
size measurements were performed with Fiji [64].
Additional files
Additional file 1: Fig. S1. Integration PCRs of parasites used in this
study. a Integration of SpZFN and LsZFN. PCR with P53/P54 amplifies the
whole Chr12 locus, resulting in 1448 bp in WT, 7850 bp for SpZFN and
7141 bp for LsZFN. The 5’ integration was amplified with P53/P12 or P53/
P24, resulting in 1226 bp and 1610 bp for SpZFN and LsZFN, respectively.
The 3’ integration was performed with P54/P55, resulting in 1181 bp.
b Integration of Sp2ZFN and Ls2ZFN. PCR of the whole locus resulted in
6758 bp or 7145 bp for Sp2ZFN and Ls2ZFN, respectively. The 5’
integration was performed with P53/P56 or P53/P24, resulting in 1226 bp
or 1610 bp for Sp2ZFN and Ls2ZFN. The 3’ integration was verified with
P54/P10 (1982 bp). c Integration of TrapZFN and Uis4ZFN. PCR of the
whole locus resulted in 6988 bp and 6970 bp for TrapZFN and Uis4ZFN,
respectively. The 5’ integration was performed with P53/P22 or P53/P38,
resulting in 1462 bp and 1504 bp for TrapZFN and Uis4ZFN, respectively.
The 3’ integration was verified with P54/P8 (2588 bp). (PDF 1088 kb)
Additional file 2: Fig. S2. Characterisation of SpZFN SI 2. a Liver stages
of parasites in HepG2 cells 48 h after sporozoite invasion. CSP staining
shows the plasma membrane of the parasite within the hepatocyte.
b C57BL/6 mice were challenged with 10,000 sporozoites i.v. or by the
bites of ten infected A. stephensi mosquitoes (bb). Peripheral blood
parasitaemia was monitored by Giemsa-stained blood smears from
three days post-infection. Percentage of mice that are blood stage
(BS) parasite free and percentage of mice alive is shown over time.
Parasitaemia over the course of the experiments is shown as growth
curves. Control infections with SpZFN resulted in no blood stage
parasitaemia. (PDF 1601 kb)
Additional file 3: Fig. S3. Alignment of zfnL and zfnLcm. (PDF 1188 kb)
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Additional file 4: Fig. S4. Liver stages of parasites in HepG2 cells 48 h
after sporozoite invasion. CSP or Uis4 staining shows the plasma
membrane of the parasite within the hepatocyte. Staining with α-GFP
antibody shows residual expression of mGFP-hDHFR fusion protein. Sizes
of liver stages from single slice images were counted 24 h and 48 h
post-sporozoite invasion. (PDF 7464 kb)
Additional file 5: Fig. S5. Overview of all microhomology sequences used
by SI parasites to repair DSBs. Microhomology sequences are shown in bold.
Ten base pairs flanking each homology region are shown prior to the DSB
break and the remaining bases in the SI parasites. The number of base pairs
lost after repair is indicated. The mismatch in the microhomology sequence
used for repair of Uis4ZFN SI 1–3 is highlighted in orange. (PDF 280 kb)
Additional file 6: Fig. S6. Results of qPCR on gDNA. a Localisation of
qPCR probes on chromosomes 12 and 13. The centromere of
chromosome 12 is shown in red. Binding sites for primer pairs used in
qPCR are shown. Primer pair C1 amplifies the product over the cutting
site of the ZFNs, while primer pairs L1 and R1 bind approximately 100 kb
away from the telomeres on the left and right arm of chromosome 12,
respectively. L2 and R2 bind around 8 kb away from the cutting site.
N1 and N2 bind on the ‘control’ chromosome 13 and are used for
normalization. b Chromosome 12 integrity is shown for samples from
salivary gland (SG) and midgut (MG). Values were normalised to N1
and N2 on chromosome 13 and to results from blood-stage gDNA
amplification. Positive and negative error is calculated from standard
error of the mean from technical duplicates. (PDF 350 kb)
Additional file 7: Fig. S7. Map of chromosomal location of multiplex
target sites using CAS9. a All perfect matches for the possible gRNA sequence
TTATATTAGTATTCGTTATTTGG targeting 104 loci of the P. berghei genome in
different bir genes and bir pseudogenes. Archived contigs represent
sequences that have not successfully been mapped to a chromosome.
b The same sequence targets 532 targets in the P. yoelii genome within
522 different yir and yir pseudogenes. c Possible gRNA sequence
GGTAACAACACAACAGCTAGTGG matches 39 targets within 31 var genes in
P. falciparum. Figures were created with Plasmodb.org [65]. (PDF 996 kb)
Additional file 8: Fig. S8. A list of all primers used in this study.
(PDF 396 kb)
Abbreviations
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